NCM
VRTX icon

Next Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Next Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-90
Closed -$15K – 217
2019
Q3 		$15K Sell
90
-76
-46% -$13.4K 0.01% 208
2019
Q2 		$30K Buy
166
+76
+84% +$13.3K 0.02% 214
2019
Q1 		$17K Hold
90
– – 0.01% 197
2018
Q4 		$15K Buy
+90
New +$15.6K 0.01% 183

Other funds holding VRTX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Next Capital Management's VRTX Position: Q4 2019 in Review

Next Capital Management sold out of Vertex Pharmaceuticals (VRTX) in Q4 2019, closing a stake of 90 shares — an estimated $15K sold.

Next Capital Management first reported a position in VRTX in Q4 2018 and held it in 4 quarters. The position peaked at $30K in Q2 2019. 813 funds tracked by Wall St. Rank hold VRTX as of Q4 2019.

  • Next Capital Management reported no remaining Vertex Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • Next Capital Management sold 90 Vertex Pharmaceuticals shares in Q4 2019, an estimated $15K.
  • Next Capital Management first reported a position in Vertex Pharmaceuticals in Q4 2018 and held it in 4 quarters.
  • Next Capital Management's Vertex Pharmaceuticals position peaked at $30K in Q2 2019.
  • 813 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2019.

Based on Next Capital Management's 13F filing for Q4 2019, filed 12 Feb 2020.